All Industries

Direxion Launches META Single Stock Leveraged and Inverse ETFs

Direxion

Following their recent success with Single Stock Leveraged and Inverse ETFs, Direxion, a leading provider of tradeable and thematic ETFs, today announced the launch of an additional pair, which allow active traders to obtain magnified, or inverse, exposure to the daily performance of the common stock of Meta Platforms, Inc. through either the Direxion Daily META Bull 2X Shares ( Ticker: METU ) or Direxion Daily META Bear 1X Shares ( Ticker: METD ). “Although Meta has been around for over two decades, the company continues to evolve and innovate, cementing itself as a lasting leader in the tech space,” said Direxion Managing Director, Edward Egilinsky. “But that’s not without periods of short-term ebbs and flows, of which traders seek to take advantage.” Offering ground-breaking products built for active traders, Direxion’s pairs of Single Stock Leveraged and Inverse ETFs are meant to be used for short-term trading purposes. These ETFs should not be viewed as buy and hold investments, but rather trading tools for traders with a high-risk tolerance. In addition, unlike traditional ETFs, or even other levered and/or inverse ETFs, these ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. "With the launch of METU and METD, Direxion is the only provider to offer Single Stock ETF pairs for all of the Magnificent Seven,” Egilinsky added. “Traders may respond tactically to headline news, earnings reports, and market sentiment for the Magnificent Seven on an individual basis via our Single Stock suite, or collectively with our recently launched QQQU and QQQD, which provide exposure to a concentrated basket of the seven companies.” All Direxion leveraged and inverse ETFs are intended only for investors with an in-depth understanding of the risks associated with seeking leveraged investment results, and who plan to actively monitor and manage their positions. There is no guarantee these ETFs will meet their objective. Please visit the Direxion Leveraged and Inverse ETF Education Center, where you will find educational brochures, videos, and a self-paced online course to help you understand if leveraged ETFs are right for you. About Direxion: Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $42.3 billion in assets under management as of March 31, 2024. For more information, please visit www.direxion.com. There is no guarantee that the Funds will achieve their investment objectives. For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214. An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing. Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. An investor could lose the full principal value of his or her investment in a single day. Investing in the Funds is not the same as investing directly in META. Technology Sector Risk — The market prices of technology related securities tend to exhibit a greater degree of market risk and sharp price fluctuations than other types of securities. These securities may fall in and out of favor with investors rapidly, which may cause sudden selling and dramatically lower market prices. Technology securities may be affected by intense competition, obsolescence of existing technology, general economic conditions and government regulation and may have limited product lines, markets, financial resources, or personnel. Meta Platforms, Inc. Investing Risk — Meta Platforms, Inc. is subject to a number of risks related to: its product offerings; business operations and financial results; government regulation and enforcement; the ability to collect and use consumer data; data, security and intellectual property; and the dual class structure of the company’s common stock, which limits the ability of shareholders to influence corporate matters. Direxion Shares Risks – An investment in each Fund involves risk, including the possible loss of principal. Each Fund is non-diversified and includes risks associated with a Fund concentrating its investments in a particular security, industry, sector, or geographic region which can result in increased volatility. A Fund's investments in derivatives such as futures contracts and swaps may pose risks in addition to, and greater than, those associated with directly investing in securities or other investments, including imperfect correlations with underlying investments or the Fund's other portfolio holdings, higher price volatility and lack of availability. As a result, the value of an investment in a Fund may change quickly and without warning. Risks of the Funds include Effects of Compounding and Market Volatility Risk, Derivatives Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Market Risk, Industry Concentration Risk, Cash Transaction Risk, Indirect Investment Risk, and risks specific to the technology sector and internet company industry. Additional risks include, for the Direxion Daily META Bull 2X Shares, Leverage Risk and Daily Correlation Risk, and for the Direxion Daily META Bear 1X Shares, Shorting or Inverse Risk as well as Daily Inverse Correlation Risk. Please see the summary and full prospectuses for a more complete description of these and other risks of the Funds. Distributor: Foreside Fund Services, LLC. Contact Details Ditto Public Relations Danielle Black, SAE direxion@dittopr.co Company Website https://www.direxion.com/

June 05, 2024 09:00 AM Eastern Daylight Time

NMTC Funded 322 Projects, Nearly 60,000 Jobs Across the U.S. in 2023

New Markets Tax Credit Coalition

The New Markets Tax Credit Coalition today released its 2024 New Markets Tax Credit (NMTC) Progress Report, the 20 th edition of the report—providing analysis of NMTC activities in 2023. The report was prepared by the NMTC Coalition, a national membership organization of Community Development Entities (CDEs) and investors organized to advocate for the NMTC. Every year since 2005, the NMTC Coalition surveys CDEs about their work, delivering billions of dollars to businesses, creating jobs, and rejuvenating the parts of the country that have been left behind. The annual NMTC Progress Report presents the findings of the CDE survey and provides policymakers and practitioners with the latest trends and successes of the NMTC. “This report shows the NMTC is an efficient and powerful tool that drives impactful investments to low-income communities,” said Phil Glynn, NMTC Coalition Board Chair and President of Travois, a Certified B Corporation®️ focused exclusively on promoting housing and economic development for American Indian, Alaska Native and Native Hawaiian communities. “Two decades after its introduction, the NMTC remains one of the federal government’s most effective tools for job creation and economic stabilization. These investments create high quality, accessible jobs in the communities that need them most.” Report highlights include: JOBS AND INVESTMENT 322 projects totaling $7.6 billion received $4.5 billion in NMTC allocation (at a ten-year cost to the federal government of $1.17 billion). Projects generated 59,332 jobs in 2023, including 33,676 permanent full-time-equivalent (FTE) jobs and 25,656 construction jobs. The federal cost per job averaged under $20,000. AREAS TARGETED Projects in 49 states, the District of Columbia, and Puerto Rico. Severe Distress: 84.5 percent of NMTC financing went to severely distressed communities and 28.1 percent to non-metropolitan counties. A record 19 projects totaling $313.9 million in allocation (7.1 percent of all allocation) were in Indian Country or in majority-Native American, Native Hawaiian, or Native Alaskan census tracts. EQUITY PRICING NMTC equity pricing increased over the course of 2023. The median price reported was $.78, ranging from $.68 to $.92. COMPONENTS OF PROJECTS Jump-starting American Manufacturing: NMTC financing supported 89 manufacturing and industrial businesses with direct loans and equity investments for working capital, new equipment, or new or renovated industrial space, including shared, light industrial space for multiple manufacturing businesses. Real Estate: NMTC financing supported the construction or renovation of 13.5 million square feet of real estate and the construction or renovation of 1,132 homes and rental units targeted at low-to-moderate-income households. STRENGTHENING COMMUNITY ASSETS Expanding Access to Healthcare: The NMTC expanded healthcare access for residents of low-income communities through 89 projects. Those projects included 49 federally qualified health centers, safety-net hospitals, and free clinics. Expanding Access to Services: Sixty-one percent of projects (195) included at least one community facility, affordable housing, a nonprofit, or social service component. Those new community resources add up to nearly 350 nonprofits, health centers, childcare centers, libraries, community centers, and other community facilities and social service providers. Forty-two projects expanded access to vocational training, college and university facilities, financial education, support for entrepreneurs, or other adult education or workforce development programs. Project Selection Trends: In comparison to early in the program (2003-2010), in recent years (2018-2023), NMTC projects are much more likely to support healthcare, manufacturing, co-located social services, food banks, and services for people experiencing homelessness. This year, 80 CDEs participated in the survey. Their answers were supplemented by data from the Office of the Comptroller of the Currency, Open Corporate, Loopnet, annual reports, and other online materials from NMTC-financed businesses and nonprofits. “Over the course of two decades, the data show the NMTC not only delivers an unprecedented level of capital to low-income rural and urban communities, but it also creates much-needed jobs—helping individuals and families thrive and, in turn, grows those local economies where they live and work. In fact, since 2003, the NMTC has created more than one million jobs,” said Coalition spokesperson Bob Rapoza. The report showcases the importance of the NMTC in providing more than two decades worth of patient, flexible capital to businesses and projects located in distressed rural and urban communities, thereby creating jobs and growing business opportunities. The NMTC financing ranges from traditional industry and community sectors to new and cutting-edge technology. Projects and businesses that benefited from the Credit in the past year include manufacturing, healthcare, schools, and many others supporting childcare, youth, and families. Rapoza notes, “This report demonstrates that the NMTC has a 20-year track record of working, and Congress should, once and for all, expand and make the Credit permanent. It has the potential to positively impact communities across the country for decades to come.” About New Markets Tax Credit Program--The New Markets Tax Credit (NMTC) was enacted in 2000 to stimulate private investment and economic growth in low-income urban neighborhoods and rural communities that lack access to the patient capital needed to support and grow businesses, create jobs, and sustain healthy local economies. Since its inception, the NMTC has generated more than one million jobs. Today, due to the NMTC, over $135 billion is hard at work in underserved communities in all 50 states, the District of Columbia, and Puerto Rico. For more information, visit www.NMTCCoalition.org. Contact Details Greg Wilson +1 571-239-7474 gregwilsonpr@gmail.com Company Website https://nmtccoalition.org/

June 05, 2024 08:41 AM Eastern Daylight Time

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Benzinga

By James Blacker, Benzinga Mainz Biomed NV (NASDAQ: MYNZ), a company that specializes in the early detection of cancer, recently shared encouraging topline results from a clinical study designed to test the next-generation version of its colorectal cancer screening tool, ColoAlert®. The company recently unveiled compelling findings from its most expansive group to date at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, as well as virtually. The comprehensive examination consisted of 690 participants from 30 reputable gastroenterology facilities in Europe and the United States, and introduced previously unexplored and unreported specimens. The results underscored the effectiveness of Mainz Biomed's multimodal screening test, marking significant advancements in colorectal cancer detection. Notable figures include a sensitivity of 92.3% for colorectal cancer, a specificity of 90.1%, a sensitivity rate of 82.2% for advanced precancerous lesions, and an impressive high-grade dysplasia detection rate of 95.8%. With the success of this study, Mainz Biomed now plans to move forward with a major clinical trial in the U.S., which will involve up to 15,000 participants. If this next trial produces positive results, the company says its next-generation tool has the potential to disrupt the at-home colorectal cancer screening market by becoming a new gold standard. “The new data read-out demonstrates that our next generation product candidate for early-stage CRC detection utilizing mRNA biomarkers, a FIT test and a proprietary AI algorithm has consistently delivered high sensitivity and specificity for both advanced adenomas and colorectal cancer,” said Guido Baechler, CEO of Mainz Biomed, “These results represent a critical milestone on our path to launching our FDA PMA pivotal study ReconAAsense, which is planned to recruit up to 15,000 patients.” Why Early Detection Matters According to the American Cancer Society’s latest publication, the incidence of colorectal cancer has increased alarmingly since the mid-1990s, continuing to rise between 1% and 2% each year in people under the age of 55. Since the mid-2000s, the mortality rate among young people has increased at a similar rate. Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths worldwide. However, it is also the most preventable, with early detection leading to survival rates above 90 %. About Mainz Biomed Founded in Germany, Mainz Biomed is becoming a leading global provider of easy-to-use diagnostic solutions for patients and healthcare providers everywhere. The company develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States and the rest of the world, and develops innovative products to quickly and reliably identify the early onset of several leading deadly conditions – such as pancreatic cancer and colorectal cancer. The company reports that its CE-IVD-cleared flagship product, ColoAlert, is the first DNA-based screening test for colorectal cancer in Europe, and that it is developing proprietary genetic testing methods for pancreatic cancer. For 2023, the company earned revenues of $895,479, which compared to revenues of $529,877 in 2022. What Sets ColoAlert Apart In a market with established players such as Cologuard from Exact Sciences Corporation (NASDAQ: EXAS), ColoAlert stands out as an innovative product that addresses the need for a convenient and user-friendly test. Mainz Biomed claims that ColoAlert is not only more effective than traditional blood tests at detecting precancerous polyps early but also detects more cases of colorectal cancer than other stool tests. As Mainz Biomed plans its upcoming major trial in the U.S., the company could be one to watch as a force in the fight against cancer. More information about the company can be found at mainzbiomed.com. Featured photo by Gerd Altmann on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 05, 2024 08:30 AM Eastern Daylight Time

Image

OncoCyte's Innovative Approach: Potential in Precision Diagnostics

RazorPitch OCX

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects. Amidst these challenges, OncoCyte Corporation (NASDAQ: OCX ) has emerged as an innovative player in the precision diagnostics market. The company's tests enhance clinical outcomes for patients undergoing organ transplants and cancer treatments. With recent strategic partnerships and regulatory advancements, OncoCyte has spearheaded transformative advancements in the field. OCX’s product portfolio includes VitaGraft, a clinical blood-based test for monitoring solid organ transplants, and GraftAssure, a research-use-only test for the same purpose. Additionally, DetermaIO and DetermaCNI are designed for oncology applications, predicting responses to immunotherapies and monitoring therapeutic efficacy, respectively. Partnerships In April 2024, OCX partnered with Bio-Rad Laboratories (NYSE: BIO) to commercialize the GraftAssure assay. This agreement leverages Bio-Rad's extensive reach and expertise in the life sciences sector, facilitating the co-marketing of GraftAssure in the U.S. and Germany. Bio-Rad holds exclusive global distribution rights outside these regions. This collaboration is pivotal for scaling OncoCyte's operations and meeting the growing demand for transplant diagnostics. The partnership also includes an option for Bio-Rad to acquire IVD commercial rights upon FDA clearance, subject to specific milestones. This option comes with a second equity investment into OncoCyte, reflecting Bio-Rad's confidence in the product's market potential. Riggs noted, "The QX600 ddPCR platform, along with their expertise in the life science market, makes Bio-Rad a natural partner for our transplant technology." Financial Performance OncoCyte's Q1 2024 financial results indicate a strategic focus on commercialization and cost-efficiency. The company reported gross proceeds of $15.8 million from an equity private placement, including a significant investment from Bio-Rad. This funding is crucial for advancing OncoCyte's product pipeline and expanding its market presence. Operational efficiency is evident, with OncoCyte reducing its cash burn to $3.9 million, reflecting a capital-efficient business model. The collaboration with Bio-Rad and the anticipated commercial launch of GraftAssure RUO test kits in Asia, the U.S., and the EU are expected to drive revenue growth and broaden the company's market reach. Riggs remarked, "The collaboration with Bio-Rad is pivotal for the upcoming launch of our GraftAssure RUO transplant rejection diagnostic test kit and central to our mission of developing accessible point-of-care diagnostics and continuous innovation in transplant rejection monitoring." Publication in New England Journal of Medicine OCX announced a significant milestone on May 30, 2024, with the publication of promising data on VitaGraft Kidney in the New England Journal of Medicine. This phase 2 study highlights VitaGraft Kidney’s potential to revolutionize kidney transplant care by accurately monitoring graft health through measuring donor-derived cell-free DNA (dd-cfDNA). For investors, this development signals substantial market potential. VitaGraft Kidney's ability to monitor therapeutic efficacy and detect disease recurrence opens new revenue streams. This test could become a standard in post-transplant care, driving repeated testing and long-term revenue. VitaGraft Kidney addresses a critical unmet need. Up to 20.2% of kidney transplant patients develop antibody-mediated rejection (AMR) within 10 years, with no FDA-approved drugs currently available for AMR management. The combination of VitaGraft testing and felzartamab therapy offers a promising solution, potentially improving patient outcomes and healthcare efficiency. OCX CEO Josh Riggs emphasized the breakthrough nature of this study, stating, “This positions VitaGraft Kidney as a crucial tool in managing transplant health. Our recent partnership with Bio-Rad expands our capacity to deliver these innovative solutions globally.” Riggs highlighted the test’s competitive edge in detecting AMR up to 10 months earlier than current protocols, enhancing patient care, and strengthening OncoCyte’s market position. The findings will be presented at the 2024 American Transplant Congress on June 3, 2024. This presentation is expected to further validate VitaGraft Kidney’s clinical value and could act as a catalyst for broader market adoption. OncoCyte’s latest publication not only validates VitaGraft Kidney’s clinical potential but also strengthens the company’s market position. As OCX continues to innovate and expand its market reach, investors can anticipate significant growth opportunities in the precision diagnostics sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by PCG Advisory Inc. to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

June 05, 2024 07:00 AM Eastern Daylight Time

Clarified Precision Medicine and xCures Form Strategic Partnership to Transform Patient Outcomes Through Precision Oncology

Clarified Precision Medicine

Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of expert medical provider review and underlying artificial intelligence (AI) computational algorithms, and xCures, a healthcare technology company that delivers real-time clinical data to power precision medicine support, today announced a strategic partnership to dramatically advance the field of precision oncology. The two companies will come together to enhance cancer-care delivery and personalized patient treatment recommendations through precision medicine and data-driven analysis. The goal of the alliance is to better identify and understand current gaps in providing precision medicine and ultimately improve patient outcomes. Oncology faces an immediate need to improve access to precision medicine. In the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting the genomic tests that make precision medicine possible — which, in turn, leads to more effective utilization of these powerful 21st-century tools. To that end, Clarified and xCures will collaborate on patient-level data analytics and work together to improve provider support, education, and communication. The two organizations will develop learning systems focused on innovative solutions in precision oncology, such as predictive analytics and treatment optimization. Clarified will contribute its specialized treatment recommendation system, which combines insights from experienced medical professionals with support from its AI-driven treatment algorithm. The company’s team of expert medical reviewers will provide clinical oversight. xCures will provide its AI-driven technology platform, which excels at extracting the critical information needed for care among the complex cancer patient data and enhancing access to medical records. “This partnership unites two of the most innovative leaders in the field of precision oncology,” said Clarified Precision Medicine CEO Rajni Natesan, MD, MBA. “Clarified is the leading expert in closing gaps at the last mile of precision oncology, with an AI platform and the greatest understanding of physician needs and individual patient outcomes. xCures is a leader in data and technology that transforms clinical efficiency and patient care. This powerful alliance enables us to overcome obstacles in cancer care that can only be addressed by an advanced, data-driven understanding of oncology at the patient level.” "We are excited to partner with Clarified Precision Medicine to harness the power of real-time clinical data and advanced analytics,” said xCures CEO Mika Newton. “This collaboration will enable us to deliver highly personalized and effective treatment recommendations, ultimately improving patient outcomes in precision oncology. By combining our strengths, we can address the critical need for better access to precision medicine and support oncologists in making data-driven decisions that enhance patient care." In addition to improving the utilization of precision medicine, the alliance will have significant capabilities in data collection and analytics to drive precision oncology research. The technology integration between Clarified and xCures will facilitate retrospective and prospective data analysis to improve treatment strategies and patient care outcomes. About Clarified Precision Medicine Clarified Precision Medicine is the first scalable molecular tumor board with a combination of ML-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit clarifiedprecisionmedicine.com About xCures Inc. Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health. Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com, or visit www.xcures.com Contact Details For Clarified Precision Medicine info@clarifiedmedicine.com Company Website https://clarifiedprecisionmedicine.com/

June 04, 2024 03:00 PM Eastern Daylight Time

VISIONARY DIRECTOR JONATHAN BAKER ANNOUNCES FINAL FILM “ICON” AND SETS PRODUCTION FOR 2025

FATE

Los Angeles, CA (May 28, 2024) - Baker Entertainment Group, a film development and production company rooted in the tradition of classic Hollywood romance by visionary filmmaker Jonathan Baker, announced today it has wrapped production on “Fate” and is looking ahead to its next and final film. Baker’s next project “ICON” will be his final act as he sets sail on his directorial career in Hollywood. ”ICON” is about a soul that moves through a hundred years until it reaches its destiny as a rock star, using one family’s saga through immigration and musical history as its backdrop. “ICON” will head into production in 2025. "I've waited my entire life to share this story," said Jonathan Baker. "This narrative of ICON is crucial to America, highlighting the significance of immigration and how it shaped our nation. Our past is integral to our identity. A film like ICON is truly unique; it blends a historical perspective with a musical lens like never before." Baker envisions a star-studded ensemble cast coming together to create what he calls “a musical masterpiece” for “ICON”. Production on Baker’s last film “Fate” has wrapped, featuring an all star cast that includes Academy Award-winning actor Faye Dunaway (“Bonnie & Clyde”, “Chinatown”), Academy Award-nominee Harvey Keitel (“Bugsy”, “Taxi Driver”), Actor, Director, Writer, Andrew McCarthy (“The Blacklist,” “Orange is the New Black”, “Brats”), Brandon Routh (“Superman Returns”), Mena Suvari (“Grace and Grit”), Cheech Marin (“From Dusk Till Dawn”), and Janet Montgomery (“Black Swan”, “Black Mirror”). “The magic of the film is that everyone is not what they appear to be”, said Academy Award-winner Faye Dunaway. Jonathan Baker spent two years crafting the cast of “Fate” by hiring against type for each role. “Fate” and “ICON” are both co-written by Micheal Buhlman and Jonathan Baker. “Fate” is currently looking for a domestic distributor who believes in theatrical releases. Highland Film Group is handling international sales which kicked off at this year's Cannes Film Festival. For more information, please visit https://www.bakerentertainmentgroup.com/. ### Contact Details Jive PR + Digital Jordan Parlee jordan@jiveprdigital.com Company Website https://www.bakerentertainmentgroup.com

June 04, 2024 02:31 PM Eastern Daylight Time

HTX Issues Security Alert Regarding Exchange Accounts Amid Rising Cyber Treats

HTX

Singapore / June 3, 2024 – In light of the increasing sophistication of recent cyberattacks targeting cryptocurrency exchange accounts, HTX, the crypto exchange giant, reportedly issued an urgent security alert to its worldwide users to enhance their security vigilance for safeguarding assets. Recent Cyberattacks and Analysis Case 1: A user's Chrome browser was infiltrated via the malicious "Aggr" plugin, resulting in the hijacking of browser cookies. Attackers exploited these cookies to access the user's account of a certain exchange without a login password and 2FA code and transfer out $1 million assets by wash trading. Case 2: Another user fell victim to a sophisticated attack where attackers purchased their personal information on Telegram. The attackers manipulated the user's exchange account through email login and the forgot password option. Subsequently, they applied to change account settings, such as phone number, email address, and even Google Authenticator with AI-generated videos. This breach culminated in the theft of over $2 million assets after 24 hours of changing the account password. These cases underscore the evolvement of cyber threats, particularly as AI technology is increasingly leveraged by malicious actors. It would be the best if users adopt robust security measures to protect their personal information and assets. For those holding substantial investments, it is critical to implement measures for stringent privacy and isolation, such as disabling third-party plugins and regularly logging out of accounts. HTX’s Commitment to User Asset Security: Timely Upgrade of Security System As a world-leading cryptocurrency exchange, HTX is unwavering in its priority for user asset security. The exchange's security team continuously enhances its security management including security reserves and real-time security upgrades to counteract emerging threats. HTX advises users to adhere to the following security practices: 1. Phone Security: When accessing HTX on smartphones, ensure your device security by avoiding the installation of untrusted third-party apps. Only download the HTX app from official app stores and authorized channels. 2. PC Security: For login via PC, ensure your device is protected with robust antivirus software. Avoid installing untrusted third-party applications and browser extensions. Moreover, HTX maintains a reserve ratio exceeding 100%, assuring users that their assets are always fully withdrawable. The exchange provides monthly disclosures of reserve ratios and open-source verification tools for Merkle tree data, wallet address ownership, and on-chain assets. Looking ahead, HTX is poised to employ even higher financial standards to ensure the long-term security of user assets. About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com/

June 04, 2024 02:11 PM Eastern Daylight Time

Mediavine Builds Out C-Suite with New Executive Promotions

Kite Hill PR

Mediavine, the largest exclusive full-service ad management firm in the U.S., is building out its C-Suite with key executive promotions. Amanda Martin is taking the newly created role of Chief Revenue Officer (CRO), while Jamie Lieberman expands her role from Chief Legal Officer to Chief Legal Officer & Chief Operations Officer (CLO/COO). These strategic additions to the leadership team enable Mediavine to proactively find solutions within the media industry while continuing to propel Mediavine’s business growth by bringing the highest value to the buy and sell sides including agencies, brands and publishers. Martin joined Mediavine over a year ago as SVP of Monetization and Business Strategy to optimize growing relationships across the buy and sell sides and has been a key representative for Mediavine in the industry. Martin will lead all revenue related activity including Sales, AdTech, Ad Operations, Partnerships & Commercial Data Strategy, while overseeing Mediavine’s growing DSP and SSP relationships. Martin will also be responsible for Mediavine’s marketing efforts which include a strategic move to tie marketing initiatives more closely to revenue. Previously, Martin served as SVP of Corporate Development and Strategic Partnerships at digital agency Goodway Group. “I have always been a firm believer that collaboration between the buy and sell sides is what yields the best results for both. This has been how I approached my role at Mediavine, helping our extensive publishing community navigate big industry changes and expand Mediavine beyond supply to highlight the audience strengths of mid to long tail publishers,” said Amanda Martin. “In my new role as CRO, I remain focused on the connection between demand generated from the buy side to the benefit of the publisher and sell side.” The strategic decision to combine the legal and operations roles at Mediavine is a reflection of the industry's changing landscape and Lieberman's experience as Mediavine's General Counsel, during which she operationalized numerous aspects of the business. This experience has allowed her to integrate processes to create a more sophisticated data-driven organization. In her new role, she continues to influence strategic direction on policies and procedures, intellectual property, contract negotiations and compliance, while also taking on Operations, including Project Management, InfoSec, IT, and Business Intelligence. "Privacy and data are two important pillars to our organization, and I am delighted to have the opportunity to oversee the legal and operations teams at Mediavine to ensure we are leading the industry through our approach,” said Jamie Lieberman. "I look forward to working closely with our team to ensure that we continue to navigate the legal and operational challenges of the digital media industry successfully." “We are excited to build out our C-Suite with the introduction of these two important roles. Amanda and Jamie have proven themselves to be highly strategic and innovative leaders who are helping to evolve our company in a way that sets us up for continued success. By streamlining operations, legal, marketing and sales, we become more agile, effective and ultimately a stronger partner to our publishers as well as brand and agency partners,” said Eric Hochberger, Mediavine Co-Founder and CEO. “I am also personally proud to expand the leadership team with two women who are strong believers in supporting and promoting other women in AdTech, a value that Mediavine and I share and will continue to champion.” About Mediavine Mediavine is the largest exclusive independent full-service ad management company, representing and monetizing approximately 11,000 publisher partner websites with 1.6 billion monthly pageviews in addition to its owned and operated properties. Mediavine proudly ranks as a Comscore top two lifestyle property with 150+ million unique monthly visitors and 17 billion monthly ad impressions. Mediavine is a Google Certified Publishing Partner - Premier, Great Place to Work®, I nc. 2022 Best Workplace, Fortune 2022 Best Medium Workplace, Ad Age 2022 Best Place to Work, and 2023 Inc. 5000. To learn more about Mediavine, visit www.mediavine.com or follow us on Twitter, Facebook, LinkedIn and Instagram. Contact Details Kite Hill PR Geanna Diaz mediavine@kitehillpr.com

June 04, 2024 11:00 AM Eastern Daylight Time

GOLDEN TECHNOLOGIES PARTNERS WITH ROBOOTER TO INTRODUCE CUTTING-EDGE MOBILITY SOLUTIONS

Robooter

OLD FORGE, PA - June 4, 2024 - ( ThriveNewsWire ) - Golden Technologies is proud to announce its collaboration with Robooter, marking a significant milestone in the mobility industry. As the exclusive distributor of Robooter's E40 in the United States, Golden Technologies is excited to offer a diverse range of innovative products to consumers. With this partnership, Golden Technologies introduces the GP303 Golden Ally powered by Robooter, a groundbreaking folding power wheelchair designed to enhance mobility and independence for users nationwide. Rich Golden, CEO of Golden Technologies, expressed his delight at the successful collaboration between the two companies, stating, "The GP303 Ally has been exceptionally well-received, and our retailers are eager to introduce this state-of-the-art product to our customers. We are thrilled to partner with Robooter and look forward to further strengthening our relationship by introducing additional products in the near future." The Golden Ally, a result of the collaboration between Golden Technologies and Robooter, combines cutting-edge technology with ergonomic design to provide users with unparalleled comfort and functionality. Featuring a tight turning radius, luxurious memory foam seating, and ergonomically designed foot positions, the Golden Ally offers users a superior mobility experience. Additionally, users can control the wheelchair remotely via a smart mobile app, further enhancing its convenience and usability. In addition to the E40 series, Robooter's X40 and E60 series offer users a comprehensive range of mobility solutions tailored to their specific needs. With the introduction of these innovative products, Golden Technologies and Robooter reaffirm their commitment to delivering exceptional quality and innovation in the mobility industry. For more information about Robooter and Golden Technologies, please visit: Robooter: https://www.robooter.com/ Golden Technologies: https://goldentech.com/ To explore our range of products, including the X40 and E60 series, please visit: Robooter X40: https://www.robooter.com/robooter-x Robooter E60: https://www.robooter.com/robooter-e60 Contact Information Keira Zhou info@robooter.com https://www.robooter.com/ Contact Details Robooter Keira Zhou info@robooter.com Company Website https://www.robooter.com/

June 04, 2024 10:00 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 3597